28071754|t|Far-infrared protects vascular endothelial cells from advanced glycation end products - induced injury via PLZF -mediated autophagy in diabetic mice
28071754|a|The accumulation of advanced glycation end products (AGEs) in diabetic patients induces vascular endothelial injury. Promyelocytic leukemia zinc finger protein (PLZF) is a transcription factor that can be activated by low-temperature far-infrared (FIR) irradiation to exert beneficial effects on the vascular endothelium. In the present study, we investigated the influence of FIR - induced PLZF activation on AGE - induced endothelial injury both in vitro and in vivo. FIR irradiation inhibited AGE - induced apoptosis in human umbilical vein endothelial cells (HUVECs). PLZF activation increased the expression of phosphatidylinositol-3 kinases (PI3K), which are important kinases in the autophagic signaling pathway. FIR - induced PLZF activation led to autophagy in HUVEC, which was mediated through the upregulation of PI3K. Immunofluorescence staining showed that AGEs were engulfed by HUVECs and localized to lysosomes. FIR - induced autophagy promoted AGEs degradation in HUVECs. In nicotinamide / streptozotocin - induced diabetic mice, FIR therapy reduced serum AGEs and AGEs deposition at the vascular endothelium. FIR therapy also reduced diabetes - induced inflammatory markers in the vascular endothelium and improved vascular endothelial function. These protective effects of FIR therapy were not found in PLZF - knockout mice. Our data suggest that FIR - induced PLZF activation in vascular endothelial cells protects the vascular endothelium in diabetic mice from AGE - induced injury.
28071754	0	12	Far-infrared	T070	C1289903
28071754	13	21	protects	T033	C1545588
28071754	22	48	vascular endothelial cells	T025	C1257792
28071754	54	85	advanced glycation end products	T109,T123	C0162574
28071754	88	95	induced	T169	C0205263
28071754	96	102	injury	T037	C0178314
28071754	107	111	PLZF	T116,T123	C1674035
28071754	122	131	autophagy	T043	C0004391
28071754	135	148	diabetic mice	T015	C0085243
28071754	169	200	advanced glycation end products	T109,T123	C0162574
28071754	202	206	AGEs	T109,T123	C0162574
28071754	211	219	diabetic	T047	C0011847
28071754	220	228	patients	T101	C0030705
28071754	229	236	induces	T169	C0205263
28071754	237	257	vascular endothelial	T024	C0014261
28071754	258	264	injury	T037	C0178314
28071754	266	308	Promyelocytic leukemia zinc finger protein	T116,T123	C1674035
28071754	310	314	PLZF	T116,T123	C1674035
28071754	321	341	transcription factor	T116,T123	C0040648
28071754	354	363	activated	T039	C2253861
28071754	367	382	low-temperature	T070	C0009264
28071754	383	395	far-infrared	T070	C1289903
28071754	397	400	FIR	T070	C1289903
28071754	402	413	irradiation	T070	C1282930
28071754	417	441	exert beneficial effects	T038	C3714634
28071754	449	469	vascular endothelium	T024	C0014261
28071754	486	491	study	T062	C2603343
28071754	496	508	investigated	T169	C1292732
28071754	513	522	influence	T077	C4054723
28071754	526	529	FIR	T070	C1289903
28071754	532	539	induced	T169	C0205263
28071754	540	544	PLZF	T116,T123	C1674035
28071754	545	555	activation	T039	C2253861
28071754	559	562	AGE	T109,T123	C0162574
28071754	565	572	induced	T169	C0205263
28071754	573	584	endothelial	T024	C0014261
28071754	585	591	injury	T037	C0178314
28071754	592	596	both	T080	C1706086
28071754	597	605	in vitro	T062	C0681828
28071754	610	617	in vivo	T062	C0681829
28071754	619	622	FIR	T070	C1289903
28071754	623	634	irradiation	T070	C1282930
28071754	635	644	inhibited	T080	C0311403
28071754	645	648	AGE	T109,T123	C0162574
28071754	651	658	induced	T169	C0205263
28071754	659	668	apoptosis	T043	C0162638
28071754	672	710	human umbilical vein endothelial cells	T025	C3179121
28071754	712	718	HUVECs	T025	C3179121
28071754	721	725	PLZF	T116,T123	C1674035
28071754	726	736	activation	T039	C2253861
28071754	737	746	increased	T081	C0205217
28071754	751	761	expression	T045	C1171362
28071754	765	795	phosphatidylinositol-3 kinases	T116,T126	C2936824
28071754	797	801	PI3K	T116,T126	C2936824
28071754	814	823	important	T080	C3898777
28071754	824	831	kinases	T116,T126	C0031727
28071754	839	849	autophagic	T043	C0004391
28071754	850	867	signaling pathway	T044	C0037080
28071754	869	872	FIR	T070	C1289903
28071754	875	882	induced	T169	C0205263
28071754	883	887	PLZF	T116,T123	C1674035
28071754	888	898	activation	T039	C2253861
28071754	906	915	autophagy	T043	C0004391
28071754	919	924	HUVEC	T025	C3179121
28071754	945	952	through	T169	C0332273
28071754	957	969	upregulation	T044	C0041904
28071754	973	977	PI3K	T116,T126	C2936824
28071754	979	997	Immunofluorescence	T059	C0016318
28071754	998	1006	staining	T059	C0487602
28071754	1019	1023	AGEs	T109,T123	C0162574
28071754	1041	1047	HUVECs	T025	C3179121
28071754	1052	1061	localized	T082	C0392752
28071754	1065	1074	lysosomes	T026	C0024369
28071754	1076	1079	FIR	T070	C1289903
28071754	1082	1089	induced	T169	C0205263
28071754	1090	1099	autophagy	T043	C0004391
28071754	1100	1108	promoted	T052	C0033414
28071754	1109	1113	AGEs	T109,T123	C0162574
28071754	1114	1125	degradation	T169	C0243125
28071754	1129	1135	HUVECs	T025	C3179121
28071754	1140	1152	nicotinamide	T109,T121,T127	C0028027
28071754	1155	1169	streptozotocin	T109,T195	C0038432
28071754	1172	1179	induced	T169	C0205263
28071754	1180	1193	diabetic mice	T015	C0085243
28071754	1195	1198	FIR	T070	C1289903
28071754	1199	1206	therapy	T061	C0087111
28071754	1207	1214	reduced	T080	C0392756
28071754	1215	1225	serum AGEs	T116	C0217068
28071754	1230	1234	AGEs	T109,T123	C0162574
28071754	1235	1245	deposition	T169	C0333562
28071754	1253	1273	vascular endothelium	T024	C0014261
28071754	1275	1278	FIR	T070	C1289903
28071754	1279	1286	therapy	T061	C0087111
28071754	1292	1299	reduced	T080	C0392756
28071754	1300	1308	diabetes	T047	C0011847
28071754	1311	1318	induced	T169	C0205263
28071754	1319	1339	inflammatory markers	T033	C4087233
28071754	1347	1367	vascular endothelium	T024	C0014261
28071754	1372	1380	improved	T033	C0184511
28071754	1381	1401	vascular endothelial	T024	C0014261
28071754	1402	1410	function	T042	C1254358
28071754	1418	1436	protective effects	T039	C3179279
28071754	1440	1443	FIR	T070	C1289903
28071754	1444	1451	therapy	T061	C0087111
28071754	1457	1466	not found	T033	C0442737
28071754	1470	1474	PLZF	T116,T123	C1674035
28071754	1477	1490	knockout mice	T015	C0206745
28071754	1496	1500	data	T078	C1511726
28071754	1501	1508	suggest	T078	C1705535
28071754	1514	1517	FIR	T070	C1289903
28071754	1520	1527	induced	T169	C0205263
28071754	1528	1532	PLZF	T116,T123	C1674035
28071754	1533	1543	activation	T039	C2253861
28071754	1547	1573	vascular endothelial cells	T025	C1257792
28071754	1587	1607	vascular endothelium	T024	C0014261
28071754	1611	1624	diabetic mice	T015	C0085243
28071754	1630	1633	AGE	T109,T123	C0162574
28071754	1636	1643	induced	T169	C0205263
28071754	1644	1650	injury	T037	C0178314